Let’s talk about NASH – The pharma opportunity everyone’s waiting for
The race to treat NASH. Several promising candidates are currently competing in a multi-billion-dollar race. NASH, or non-alcoholic steatohepatitis, affects millions of patients world-wide and by 2020 is projected to replace hepatitis C as the number one reason for liver transplantation in the United States.
Multiple drug developers have taken on the challenge and a variety of different approaches are currently in the pipeline to tackle this complex, silent disease. Now all eyes are on the finish line to see who will be the first to enter this lucrative and untapped market.
Understanding the bigger picture of NAFLD
Non-alcoholic fatty liver disease (NAFLD) is an umbrella of disorders characterized by the accumulation of excess fat in the liver of people who drink little or no alcohol. NAFLD is the most common chronic liver condition in the world with a global prevalence estimated to be 25.2.%4 In the United States, NAFLD is the most common form of chronic liver disease, affecting about one-quarter of the population. In 2017 the direct lifetime costs associated with NAFLD were $222.6 billion; $95.4 billion of this was just for patients with an advanced form of liver disease known as non-alcoholic steatohepatitis or NASH.
Who is at risk?
A wide range of diseases and conditions can increase the risk of NAFLD including obesity, type 2 diabetes, hypertriglyceridemia, insulin resistance, and hypertension. In fact, studies have shown that NAFLD may be present in up to 70% of patients with diabetes.
What is NASH?
Up to 30% of people with NAFLD will develop NASH, a more progressive type of liver disease. NASH is associated with hepatocellular ballooning and inflammation, in addition to hepatic steatosis. About 20% of people with NASH will go on to develop scarring (fibrosis) of the liver, which may become severe enough to affect the liver’s function, conferring an increased risk of liver cirrhosis or liver cancer. Overall, the global prevalence of NASH is estimated to be 1.5%-6.5% and it is predicted to become the leading indication for liver transplantation in the next few years.
Peter Hempshall, CEO of Deallus, is partnering with Rita Numerof, Founder & President of Numerof & Associates, for a discussion series centered on the lasting impact that COVID-19 will have on business models in the healthcare industry. Tune in to be part of a discussion on how the pandemic has accelerated key market shifts, how organizations will need to operate differently, and what solutions can be offered for successfully moving businesses forward in this new reality.
We are very pleased to welcome Yacine Amrani to our Deallus team as Senior Principal. Yacine brings a strong background in Market Access, pricing and U.S. Managed Markets including extensive payer, access, pricing and reimbursement capabilities. Yacine has led engagements across multiple therapeutic areas both in the U.S and overseas for leading pharma players as well as biotech firms.
As the COVID-19 pandemic continues to impact patients, healthcare systems, and global economic outlooks, we focus on the key considerations and strategies for pharma companies when the data generation for possible therapies is becoming increasingly complex to analyze. There are several COVID-19 treatment and vaccine databases containing an aggregation of publicly-available information from validated sources detailing treatments and vaccines currently in development.
As COVID-19 continues to disrupt normalcy across the globe, China is responding with innovation in online health delivery and telemedicine. How has China encouraged telemedicine uptake? What are the factors contributing to China’s relatively quick utilization of telemedicine in the face of COVID-19? And what learnings can we gain from taking a closer look? We explore these questions in our latest addition to our COVID-19+Pharma Series.